52North raises £3.2 million to bring finger-prick cancer test closer to patients
52North, a University of Cambridge spin-out and a company that Milltrust Ventures invested in 2022 via the Future Health Fund, has raised £3.2 million in an early-stage funding round to accelerate clinical validation, regulatory progression and the UK launch of its lead product, Neutrocheck — a rapid, finger-prick blood test built to catch one of chemotherapy's most dangerous complications before it becomes an emergency.

A test built to ease pressure on emergency care Neutrocheck lets chemotherapy patients be triaged remotely for neutropenic sepsis, a life-threatening complication that drives tens of thousands of emergency hospital visits every year. Research suggests roughly two in five of those visits turn out to be false alarms — a meaningful burden on both patients and stretched health systems. Neutrocheck is the first application of 52North's Aster platform, a biomarker detection technology designed to move diagnostics out of the hospital and into patients' hands.
Backed by a strong investor syndicate The round was co-led by Macmillan Ventures and Hargreave Hale AIM VCT, with participation from existing investors Cedars-Sinai Intellectual Property Company, Cancer Research Horizons, the University of Cambridge and OKG Capital, alongside a grant from Innovate UK's Investor Partnerships programme. Total equity funding in the company now exceeds £7.5 million.
This is the first investment led by Macmillan Ventures, the newly launched venture arm of Macmillan Cancer Support, while Hargreave Hale AIM VCT joins as a new investor with a £1.0 million commitment — the largest from a new backer in 52North's history.
What they're saying "This round is another powerful vote of confidence in our platform and the team behind it," said Umaima Ahmad, chief executive officer and co-founder of 52North. The funding, she added, will help bring "faster, more convenient and more personalised urgent cancer care."
Felix Litzkow, head of Macmillan Ventures and incoming board director at 52North, said the company's platform is "exactly the kind of innovation Macmillan Ventures was created to back."
Why it matters to us
A charity launching a venture arm, and leading its first deal points to a wider shift toward funding technologies that ease strain on overstretched health systems. For 52North, the raise moves a hospital-grade diagnostic closer to the patient, and closer to market. It's the kind of science-led, patient-capital story that sits squarely within the thesis of Milltrust's Future Health Fund, which backs early-stage innovation across human health, food security and sustainability.
For anyone who wishes to learn more about our body of work in private markets investing, or to discuss opportunities alongside us, we welcome the chance to connect further via mv@milltrust.com.



